Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 15/20 | 0.82 |
| ▸ | RAD52 | P43351 | 1/20 | 0.81 |
| ▸ | BRD4 | O60885 | 7/20 | 0.71 |
| ▸ | BRDT | Q58F21 | 7/20 | 0.71 |
| ▸ | TTK | P33981 | 2/20 | 0.63 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.63 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.60 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4305052 | 1.00 | PLK1 (0.82) | PLK1RAD52BRD4BRDTTTK | |
| SCHEMBL4295279 | 1.00 | PLK1 (0.82) | PLK1RAD52BRD4BRDTTTK | |
| SCHEMBL3546277 | 0.99 | PLK1 (0.82) | PLK1RAD52BRD4BRDTTTK | |
| SCHEMBL4300694 | 0.97 | PLK1 (0.82) | PLK1RAD52BRD4BRDTTTK | |
| SCHEMBL4301986 | 0.97 | PLK1 (0.82) | PLK1RAD52BRD4BRDTTTK | |
| SCHEMBL4304227 | 0.97 | PLK1 (0.82) | PLK1RAD52BRD4BRDTTTK | |
| SCHEMBL1202746 | 0.93 | PLK1 (0.86) | PLK1RAD52BRD4BRDTTTK | |
| SCHEMBL1202517 | 0.93 | PLK1 (0.94) | PLK1RAD52BRD4BRDTTTK | |
| SCHEMBL4294930 | 0.91 | PLK1 (0.81) | PLK1RAD52BRD4BRDTTTK | |
| SCHEMBL4294926 | 0.91 | PLK1 (0.81) | PLK1RAD52BRD4BRDTTTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291938-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-26 | — | — | US | claimed |
| US-20090291938-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090291938-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090291938-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| WO-2009067547-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291938-A1 | POLO-LIKE KINASE INHIBITORS | PLK1, PLK2, POLK | PLK1 1/4885RAD52 1250/4885BRD4 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.